Navigation Links
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Date:6/9/2009

at Yale University and is board certified in Neurology.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).

NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 study in patients with refractory solid tumors.

Nektar technology is used in nine approved partnered products in the U.S. or Europe today, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's technology platform, Nektar's pipeline of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nektar Therapeutics Reports First Quarter 2009 Financial Results
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
5. Nektar Announces Retirement of Irwin Lerner from Board of Directors
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... June 30, 2015. Biorem,s complete second quarter financial statements and MD&A ... HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , Six -months endedJune ... 2015 , 2014 Revenue , 4,709 ... Gross profit , 1,656 , 56 , ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... , ... August 26, 2015 , ... ... increasing its investment in the development and manufacture of highly valued cardiac markers ... company’s scientific team's extensive expertise with protein chemistry has led to the development ...
(Date:8/26/2015)... HONG KONG , Aug. 26, 2015 ... "Company"), China,s leading provider of ... and stem cell storage services, today announced that the ... Holdings Limited ("MO2"), an entity wholly owned by Mr. ... the Company, has acquired the outstanding shares (the "Shares") ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... 24 hours a day now that a new company has ... Web site MusicMadeInMadison.com plays more than 450 songs ... Daedalus Burn, Infinite Helix and They Drive By Night. Founded ... is to help both the circulation of the artists and ...
... succeed both personally and professionally. , ,You should make sure ... business world and your community. Once these partnerships are built, ... your needs and goals. At the same, make sure you ... , ,Relationships need to be mutually beneficial for all parties. ...
... Venture Forum was held two weeks ago in Los ... to an audience of several hundred venture capital, strategic ... interest to Midwest technology entrepreneurs as there were several ... forum is organized by the Larta Institute. Based in ...
Cached Biology Technology:Don't forget building relationships when building business 2Don't forget building relationships when building business 3Don't forget building relationships when building business 4Midwest fares surprisingly well at Venture Forum in Los Angeles 2Midwest fares surprisingly well at Venture Forum in Los Angeles 3Midwest fares surprisingly well at Venture Forum in Los Angeles 4
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... paper authored by San Diego Zoo Institute for Conservation ... the endangered California condor in the wild are human ... juvenile and adult birds. , The study documents ... sitesCalifornia, Arizona and Baja, California, Mexicofrom the inception of ...
... by Kasturi Haldar and Souvik Bhattacharjee of the University ... has made a fundamental discovery in understanding how malaria ... parasites target proteins to the surface of the red ... vessels. Strategies that prevent this host-targeting process will block ...
... for the Study of Bioethical Issues will hold a ... Following its report on Human Subjects Protections, the ... children, whole genome sequencing and neuroethics. Medical ... Health and Human Services Kathleen Sebelius asked the Commission ...
Cached Biology News:Scientific paper shows California condor still threatened by human activities 2Notre Dame researchers report fundamental malaria discovery 2Bioethics commission to meet in February in San Francisco 2
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, problems ... royalties for your hard work and endeavour! Bring ... up and market it internationally. We work under ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
Topoisomerase I...
... Topoisomerase I from vaccinia virus is ... both positive and negative superhelical turns (also ... closed DNA. The product of the reaction ... fewer positive or negative superhelical turns. DNA ...
Biology Products: